External Quality Assurance Schemes
We will be expanding and updating the information available on our External Quality Assurance Schemes soon. In the meantime if you have any questions or would like to subscribe to one of the ERNDIM EQA schemes please contact us
SUBSCRIPTIONS FOR THE ERNDIM 2018 EQA SCHEMES CLOSED ON 14TH NOVEMBER 2017.
If you are an existing ERNDIM EQA participant you will have been sent details of how to register for the 2018 EQA schemes on the ERNDIM Registration Website. If you missed the registration period but would still like to register for the 2018 EQA schemes please contact us as soon as possible however availability will be limited.
If you have any problems accessing the ERNDIM Registration Website please contact us.
If you don't already subscribe to an ERNDIM EQA Scheme and would like to participate during 2018, subscription to a scheme may still possible after the 14th November 2017 but availability will be limited.
PLEASE NOTE THE FOLLOWING 2018 SCHEMES ARE NOW FULL: ACYLCARNITINES IN SERUM, CDG, LYSOSOMAL ENZYMES IN FIBROBLASTS, NEUROTRANSMITTERS IN CSF, PTERINS IN URINE, PURINES & PYRIMIDINES IN URINE, QUANTITATIVE AMINO ACIDS, QUANTITATIVE ORGANIC ACIDS, SPECIAL ASSAYS IN URINE.
The ERNDIM EQA Scheme Catalogue - see link on right - gives information on all of the ERNDIM EQA schemes and also the prices of each scheme in Euro, GB pounds and US dollars.
Brief information on the EQA schemes offered by ERNDIM in 2018 is also below.
- Acylcarnitines in serum
- Cystine in white blood cells
- Lysosomal enzymes in fibroblasts
- Neurotransmitters in CSF
- Pterins in urine
- Purines and pyrimidines in urine
- Quantitative Amino Acids in serum
- Quantitative Organic Acids in urine
- Special Assays in serum
- Special Assays in urine
Quantitative schemes are planned and managed by members of the ERNDIM Scientific Advisory Board and organised in partnership with SKML, a Quality Assurance provider based in the Netherlands.
SKML dispatches EQA samples to scheme participants and provides a website for on-line submission of results and access to scheme reports by participants.
Existing quantitative scheme participants can log on to the results submission website here.
- Acylcarnitines in dried blood spots (3 centres)
- Congenital disorders of glycosylation in plasma/serum
- Diagnostic proficiency testing in urine (5 centres)
- Qualitative organic acids in urine (3 centres)
- Urine mucopolysaccharides
Qualitative schemes are planned and managed by members of the ERNDIM Scientific Advisory Board. The Congenital Disorders of Glycosylation schemes is organised by an academic centre. The Acylcarnitines in DBS, Diagnostic Proficiency Testing (DPT), Qualitative Organic Acids and Urine mucopolysaccharides (MPS) schemes are organised in partnership with CSCQ, a Quality Assurance provider based in Switzerland.
CSCQ dispatches Acylcarnitines in DBS, DPT, Qualitative Organic Acids and Urine MPS EQA samples to the scheme participants. CSCQ also provides a website for on-line submission of results and access to scheme reports for the DPT, Qualitative Organic Acids and Urine MPS schemes. It is planned that all qualitative schemes will be organised by CSCQ in the near future.
Existing DPT, Qualitative Organic Acids and Urine MPS scheme participants can log on to the CSCQ results submission website here.
Pilot schemes are planned, managed and organised by individuals with expertise in the relevant area. The schemes are monitored by the ERNDIM Scientific Advisory Board for a minimum period of 2 years. If after this time the Scientific Advisory Board is satisfied that the scheme is successful it will recommend that the Executive Committee adopts the scheme as an official ERNDIM EQA Scheme.
In 2018 we are running 2 pilot schemes:
1. Cognitive Amino Acids
2. Special Assays in dried blood spots
Participation in pilot schemes is limited but if you would like to be contacted if it is possible for us to widen participation in these schemes please contact us.
We would also like to hear about suggestions for new schemes that we might consider in the future. If you would like to comment please contact us.